Maverick Capital Ltd
13F filer · CIK 0000934639Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$11.3BU.S. long equity reported on 13F
Positions17683 new · 146 closed
Net flow last quarter-$20.1MBuys minus sells
Top 10 positions weight42.8%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 2026176 positions | |||||
| $612M | 5.40% | 0.01% | -3.7% | Q1 2016 | |
| $567M | 5.01% | 0.06% | +44.3% | Q3 2019 | |
| $515M | 4.55% | 0.62% | +11.7% | Q1 2024 | |
| $512M | 4.53% | 0.07% | +22.5% | Q4 2015 | |
| $510M | 4.50% | Not reported | +65.3% | Q4 2015 | |
| $482M | 4.25% | 0.02% | -12.8% | Q2 2017 | |
| $475M | 4.20% | Not reported | +58.4% | Q1 2023 | |
| $430M | 3.80% | Not reported | Not reported | Q3 2013 | |
| $375M | 3.31% | Not reported | +165.0% | Q1 2024 | |
| $368M | 3.25% | 0.94% | +15.8% | Q1 2024 | |
| $340M | 3.00% | 0.00% | -42.5% | Q1 2016 | |
| $334M | 2.95% | 1.57% | +41.1% | Q1 2019 | |
| $310M | 2.74% | 0.01% | +14.7% | Q1 2015 | |
| $294M | 2.60% | 0.12% | +13.6% | Q4 2020 | |
| $278M | 2.45% | 0.23% | +10.9% | Q2 2013 | |
| $271M | 2.39% | 3.52% | +30.7% | Q1 2021 | |
| $264M | 2.33% | 0.09% | +156.9% | Q2 2016 | |
| $258M | 2.28% | 0.04% | -6.8% | Q2 2017 | |
| $253M | 2.24% | 0.40% | +41.5% | Q1 2018 | |
| $253M | 2.23% | 0.27% | +6.7% | Q1 2018 | |
| $252M | 2.22% | 3.43% | New | Q2 2026 | |
| $249M | 2.20% | 0.28% | Not reported | Q1 2021 | |
| $229M | 2.03% | 0.99% | Not reported | Q1 2025 | |
| $198M | 1.75% | 0.24% | +46.8% | Q1 2015 | |
| $195M | 1.73% | 1.70% | -8.6% | Q4 2023 | |
| $188M | 1.66% | 0.49% | Not reported | Q3 2014 | |
| $174M | 1.53% | Not reported | +25.6% | Q2 2020 | |
| $168M | 1.48% | 2.61% | -11.2% | Q4 2023 | |
| $163M | 1.44% | 0.05% | +56.2% | Q3 2018 | |
| $141M | 1.25% | 0.81% | Not reported | Q3 2020 | |
| $120M | 1.06% | 1.46% | Not reported | Q3 2019 | |
| $111M | 0.98% | 2.78% | +49.5% | Q4 2024 | |
| $108M | 0.96% | 0.98% | -67.6% | Q4 2019 | |
| $100M | 0.88% | 0.39% | +73.9% | Q1 2026 | |
| $97.3M | 0.86% | 1.37% | +31.2% | Q3 2021 | |
| $97.1M | 0.86% | 1.89% | New | Q2 2026 | |
| $94M | 0.83% | 27.97% | +97.9% | Q1 2024 | |
| $93.8M | 0.83% | 1.11% | +17.1% | Q1 2024 | |
| $79.3M | 0.70% | Not reported | -20.5% | Q3 2020 | |
| $72.9M | 0.64% | 0.78% | +14.3% | Q2 2021 | |
| $67.9M | 0.60% | 1.64% | +37.1% | Q4 2020 | |
| $61M | 0.54% | 1.01% | New | Q2 2026 | |
| $59.7M | 0.53% | 5.32% | +1.2% | Q1 2021 | |
| $42.6M | 0.38% | 1.33% | +32.6% | Q4 2025 | |
| $16.6M | 0.15% | 6.44% | Not reported | Q1 2023 | |
| $13.4M | 0.12% | 3.58% | +10.0% | Q2 2021 | |
| $5.33M | 0.05% | 0.05% | New | Q2 2026 | |
| $4.67M | 0.04% | 0.01% | +10.5% | Q3 2023 | |
| $4.66M | 0.04% | 0.32% | Not reported | Q2 2019 | |
| $4.58M | 0.04% | 0.04% | New | Q2 2026 | |
| Q1 2026Reported May 15, 2026239 positions | |||||
| $554M | 6.39% | 0.01% | +6.3% | Q1 2016 | |
| $483M | 5.57% | 0.02% | -2.7% | Q2 2017 | |
| $418M | 4.82% | 0.00% | -25.4% | Q1 2016 | |
| $341M | 3.94% | 0.07% | -1.0% | Q2 2013 | |
| $323M | 3.72% | Not reported | +91.6% | Q1 2023 | |
| $297M | 3.43% | 0.11% | -23.1% | Q3 2016 | |
| $269M | 3.10% | 0.01% | -36.9% | Q1 2015 | |
| $263M | 3.04% | 0.10% | -0.3% | Q4 2020 | |
| $263M | 3.04% | 0.28% | +42.5% | Q1 2018 | |
| $253M | 2.92% | 3.33% | +5.9% | Q4 2025 | |
| $250M | 2.89% | Not reported | -23.6% | Q4 2015 | |
| $248M | 2.86% | 3.03% | +23.1% | Q4 2019 | |
| $244M | 2.81% | 0.04% | +3.9% | Q2 2017 | |
| $234M | 2.70% | 0.82% | +24.1% | Q1 2024 | |
| $228M | 2.63% | 0.20% | -3.7% | Q2 2013 | |
| $211M | 2.44% | 0.09% | Not reported | Q1 2021 | |
| $207M | 2.39% | 1.11% | +25.3% | Q1 2019 | |
| $196M | 2.26% | 114.29% | New | Q1 2026 | |
| $185M | 2.13% | 2.94% | +3.9% | Q4 2023 | |
| $182M | 2.10% | 1.83% | +1.6% | Q4 2023 | |
| $181M | 2.08% | 0.10% | Not reported | Q3 2019 | |
| $179M | 2.06% | 2.69% | Not reported | Q1 2021 | |
| $179M | 2.06% | 0.25% | -8.5% | Q1 2018 | |
| $161M | 1.85% | Not reported | -23.4% | Q1 2024 | |
| $155M | 1.79% | 0.12% | Not reported | Q2 2020 | |
| $138M | 1.59% | 0.04% | Not reported | Q3 2019 | |
| $132M | 1.52% | 0.06% | Not reported | Q4 2015 | |
| $132M | 1.52% | Not reported | -9.0% | Q2 2020 | |
| $126M | 1.45% | 0.16% | +37.8% | Q1 2015 | |
| $105M | 1.21% | 0.56% | -2.1% | Q1 2024 | |
| $97.7M | 1.13% | 0.03% | -17.8% | Q3 2018 | |
| $93.8M | 1.08% | 0.04% | -73.9% | Q2 2016 | |
| $91.4M | 1.05% | 0.04% | +2261.7% | Q1 2016 | |
| $86.1M | 0.99% | 1.24% | Not reported | Q3 2018 | |
| $80.1M | 0.92% | 0.95% | +1.7% | Q1 2024 | |
| $76.4M | 0.88% | Not reported | Not reported | Q3 2020 | |
| $73.7M | 0.85% | 5.28% | +9.5% | Q1 2021 | |
| CPCNTACentessa Pharmaceuticals PLC | $73.7M | 0.85% | 1.20% | +12.8% | Q4 2025 |
| $70M | 0.81% | 1.87% | +15.4% | Q4 2024 | |
| $66M | 0.76% | 1.00% | Not reported | Q3 2021 | |
| $50.9M | 0.59% | 0.04% | Not reported | Q3 2018 | |
| $49.3M | 0.57% | 14.13% | Not reported | Q1 2024 | |
| $49.2M | 0.57% | 1.20% | +46.9% | Q4 2020 | |
| $46.5M | 0.54% | 0.05% | +2.9% | Q1 2015 | |
| $45.1M | 0.52% | 0.23% | New | Q1 2026 | |
| $37.8M | 0.44% | 0.69% | -59.1% | Q2 2021 | |
| $35.4M | 0.41% | Not reported | Not reported | Q4 2025 | |
| $30.7M | 0.35% | 1.45% | +45.1% | Q2 2014 | |
| $24.7M | 0.28% | 6.71% | Not reported | Q1 2023 | |
| $18.6M | 0.21% | 0.02% | Not reported | Q4 2020 | |
| Q4 2025Reported Feb 13, 2026178 positions | |||||
| $557M | 5.98% | 0.01% | +39.3% | Q1 2016 | |
| $556M | 5.97% | 0.02% | +23.5% | Q1 2015 | |
| $550M | 5.90% | 0.02% | +6.5% | Q2 2017 | |
| $504M | 5.41% | 0.01% | +62.7% | Q1 2016 | |
| $358M | 3.85% | Not reported | Not reported | Q4 2015 | |
| $349M | 3.75% | 0.14% | +34.2% | Q2 2016 | |
| $314M | 3.37% | 0.21% | +19.6% | Q2 2013 | |
| $304M | 3.26% | 0.22% | +17.7% | Q1 2015 | |
| $291M | 3.12% | 0.14% | Not reported | Q3 2016 | |
| $281M | 3.01% | 0.20% | Not reported | Q1 2018 | |
| $279M | 3.00% | 0.07% | +37.1% | Q2 2013 | |
| $272M | 2.92% | 0.04% | Not reported | Q2 2017 | |
| $251M | 2.69% | 0.10% | +0.7% | Q4 2020 | |
| $226M | 2.43% | 2.47% | +27.8% | Q4 2019 | |
| $216M | 2.32% | 0.68% | -29.2% | Q1 2024 | |
| $216M | 2.32% | Not reported | +216.5% | Q1 2024 | |
| $206M | 2.22% | 0.28% | +100.7% | Q1 2018 | |
| $202M | 2.17% | 1.76% | Not reported | Q4 2023 | |
| $196M | 2.10% | Not reported | -44.2% | Q1 2023 | |
| $195M | 2.09% | Not reported | +112.3% | Q2 2020 | |
| $165M | 1.77% | 0.89% | +56.5% | Q1 2019 | |
| $164M | 1.76% | 2.84% | +4.8% | Q4 2023 | |
| $162M | 1.74% | 0.57% | -5.5% | Q1 2024 | |
| $158M | 1.69% | 4.95% | +10.6% | Q1 2021 | |
| $138M | 1.48% | 3.16% | New | Q4 2025 | |
| $134M | 1.43% | 2.24% | Not reported | Q2 2021 | |
| $125M | 1.34% | 0.07% | +44.0% | Q4 2017 | |
| $121M | 1.30% | 3.34% | -10.9% | Q2 2018 | |
| $109M | 1.17% | 0.04% | +7103.1% | Q3 2018 | |
| $108M | 1.16% | 0.05% | +3723.0% | Q2 2013 | |
| $102M | 1.09% | 0.54% | -0.9% | Q4 2018 | |
| CTCDTXCidara Therapeutics, Inc. | $101M | 1.08% | 1.45% | +9.2% | Q3 2025 |
| $92.1M | 0.99% | 0.11% | -25.9% | Q1 2015 | |
| $87.2M | 0.94% | 0.80% | -2.6% | Q4 2023 | |
| $81.3M | 0.87% | Not reported | +6200.4% | Q4 2020 | |
| $80.4M | 0.86% | 0.04% | -56.4% | Q2 2018 | |
| $66.4M | 0.71% | 1.66% | +25.9% | Q4 2024 | |
| $62.5M | 0.67% | 1.03% | +5.0% | Q1 2024 | |
| $52.7M | 0.57% | 0.05% | +52.1% | Q1 2015 | |
| $52.5M | 0.56% | 0.49% | +13.1% | Q4 2020 | |
| $49.5M | 0.53% | 0.07% | -19.9% | Q1 2021 | |
| $46.9M | 0.50% | 6.73% | Not reported | Q1 2023 | |
| $42.9M | 0.46% | 0.82% | -69.8% | Q4 2020 | |
| $42.2M | 0.45% | 1.66% | Not reported | Q2 2024 | |
| $42M | 0.45% | 0.07% | +25.8% | Q1 2023 | |
| CPCNTACentessa Pharmaceuticals PLC | $41.1M | 0.44% | 1.10% | New | Q4 2025 |
| $40.2M | 0.43% | 0.11% | +39.6% | Q2 2024 | |
| $33.4M | 0.36% | Not reported | New | Q4 2025 | |
| $32.3M | 0.35% | Not reported | -34.0% | Q1 2021 | |
| $19.5M | 0.21% | 0.17% | Not reported | Q3 2020 | |
| Q3 2025Reported Nov 14, 2025201 positions | |||||
| $491M | 6.56% | 0.02% | +8.6% | Q2 2017 | |
| $483M | 6.45% | 0.01% | +23.7% | Q1 2015 | |
| $400M | 5.34% | 0.01% | -27.6% | Q1 2016 | |
| $336M | 4.49% | Not reported | -3.4% | Q1 2023 | |
| $285M | 3.81% | 0.00% | -42.1% | Q1 2016 | |
| $264M | 3.52% | 0.19% | Not reported | Q1 2015 | |
| $263M | 3.52% | 0.10% | +9.5% | Q2 2016 | |
| $230M | 3.08% | 0.17% | -2.8% | Q2 2013 | |
| $227M | 3.04% | 0.10% | Not reported | Q4 2020 | |
| $215M | 2.87% | 0.97% | -10.5% | Q1 2024 | |
| $202M | 2.70% | 0.61% | Not reported | Q1 2024 | |
| $195M | 2.61% | 0.63% | +15.7% | Q1 2025 | |
| $186M | 2.48% | 0.09% | +7.4% | Q2 2018 | |
| $184M | 2.46% | 0.05% | Not reported | Q2 2013 | |
| $171M | 2.29% | 0.05% | +3.8% | Q3 2020 | |
| $168M | 2.24% | 1.93% | Not reported | Q4 2019 | |
| $153M | 2.05% | 2.71% | -2.0% | Q4 2023 | |
| $151M | 2.02% | 0.06% | -20.4% | Q3 2019 | |
| $134M | 1.79% | 2.72% | +16.7% | Q4 2020 | |
| $133M | 1.77% | 0.15% | +22375.8% | Q1 2015 | |
| $127M | 1.70% | 0.09% | +72.7% | Q2 2020 | |
| $121M | 1.62% | 3.75% | +13966.0% | Q2 2018 | |
| $118M | 1.58% | 0.57% | Not reported | Q1 2019 | |
| $97.2M | 1.30% | 0.55% | +15.9% | Q4 2018 | |
| $94.5M | 1.26% | 0.31% | -18.4% | Q1 2025 | |
| $90.3M | 1.21% | 0.14% | Not reported | Q1 2018 | |
| $86.9M | 1.16% | 0.37% | -1.8% | Q4 2018 | |
| $83.1M | 1.11% | 0.05% | Not reported | Q4 2017 | |
| $82.1M | 1.10% | Not reported | Not reported | Q2 2020 | |
| $79.5M | 1.06% | Not reported | Not reported | Q2 2020 | |
| $75.2M | 1.00% | Not reported | -43.3% | Q1 2024 | |
| $74.4M | 0.99% | 3.32% | +17.8% | Q2 2014 | |
| $73.1M | 0.98% | 0.75% | -8.3% | Q4 2023 | |
| $66.8M | 0.89% | Not reported | -1.4% | Q1 2021 | |
| $63.6M | 0.85% | 0.08% | -47.8% | Q1 2021 | |
| $61.4M | 0.82% | 5.24% | +1.6% | Q1 2021 | |
| $60.2M | 0.80% | 13.81% | -51.2% | Q1 2024 | |
| $59.3M | 0.79% | 0.40% | Not reported | Q1 2024 | |
| $57M | 0.76% | 0.06% | +4.2% | Q1 2023 | |
| $55.3M | 0.74% | 0.16% | -64.4% | Q3 2020 | |
| $48.6M | 0.65% | 0.44% | -33.9% | Q4 2020 | |
| $47.8M | 0.64% | 2.69% | -2.0% | Q4 2023 | |
| $46.5M | 0.62% | 0.99% | -1.6% | Q1 2024 | |
| $42.8M | 0.57% | 1.33% | -1.8% | Q4 2024 | |
| $42.5M | 0.57% | 0.17% | Not reported | Q1 2021 | |
| $40.2M | 0.54% | 0.03% | -1.7% | Q1 2015 | |
| CTCDTXCidara Therapeutics, Inc. | $40M | 0.53% | 1.42% | New | Q3 2025 |
| $37.3M | 0.50% | 0.46% | -30.5% | Q1 2025 | |
| $34M | 0.45% | 0.08% | -54.8% | Q2 2024 | |
| $27.6M | 0.37% | 7.83% | +1.3% | Q2 2021 | |
Premium opens every quarter this fund has filed